Title |
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
|
---|---|
Published in |
Clinical Cancer Research, November 2011
|
DOI | 10.1158/1078-0432.ccr-11-1595 |
Pubmed ID | |
Authors |
Evan J. Lipson, Charles G. Drake |
Abstract |
Ipilimumab (MDX-010, Yervoy; Bristol-Myers Squibb), a fully human monoclonal antibody against CTL antigen 4 (CTLA-4), was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma. In both early- and late-phase trials, ipilimumab has shown consistent activity against melanoma. For example, in a randomized phase III trial that enrolled patients with previously treated metastatic disease, ipilimumab, with or without a peptide vaccine, improved overall survival: Median overall survival was 10.1 and 10.0 months in the ipilimumab and ipilimumab plus vaccine arms, respectively, versus 6.4 months in the vaccine-alone group (hazard ratio, 0.68; P ≤ 0.003). Serious (grade 3-5) immune-related adverse events occurred in 10% to 15% of patients. Thus, although it provides a clear survival benefit, ipilimumab administration requires careful patient monitoring and sometimes necessitates treatment with immune-suppressive therapy. Here, we review the mechanism of action, preclinical data, and multiple clinical trials that led to FDA approval of ipilimumab for metastatic melanoma. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 4 | <1% |
United Kingdom | 3 | <1% |
Ecuador | 1 | <1% |
South Africa | 1 | <1% |
Japan | 1 | <1% |
Denmark | 1 | <1% |
Unknown | 482 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 81 | 16% |
Student > Ph. D. Student | 71 | 14% |
Student > Master | 62 | 13% |
Researcher | 59 | 12% |
Other | 34 | 7% |
Other | 76 | 15% |
Unknown | 110 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 104 | 21% |
Biochemistry, Genetics and Molecular Biology | 89 | 18% |
Agricultural and Biological Sciences | 87 | 18% |
Immunology and Microbiology | 38 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 17 | 3% |
Other | 39 | 8% |
Unknown | 119 | 24% |